Acumapimod (BCT-197) is an oral p38 MAP kinase inhibitor and an anti-inflammatory agent developed by Mereo BioPharma that has completed Phase 2 development as first-line therapy for severe acute exacerbations of chronic obstructive pulmonary disease. Another study on acute kidney injury in patients undergoing cardiac surgery had been discontinued. Acumapimod is an inhibitor of p38a with an IC50 value < 1 uM. Previous studies undertaken by Novartis, showed the drug has the capacity to reduce the inflammatory marker TNFα and to increase FEV1.

Cupric cyanide represents an amorphous yellow powder insoluble in water. It is used in organic synthesis as the catalyst. Acute copper poisoning after ingestion can cause liver injury, methemoglobinemia, and hemolytic anemia. Acute renal failure may result, secondary to massive hemoglobinuria.